---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-037053"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T04:59:55.038838+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# CervoMed Phase 2b DLB trial fails primary and secondary endpoints; neflamapimod no better than placebo

## Summary
- Neflamapimod did not demonstrate statistically significant effects vs placebo on CDR-SB, TUG, NTD, or CGIC at 16 weeks.
- Target plasma drug concentrations were not achieved during double-blind phase, likely negatively impacting results.
- Favorable safety/tolerability profile with no new safety signal identified.
- Company pausing all Phase 3 preparations for early-stage DLB until full analysis complete.
- Full double-blind data expected January 2025; open-label first 16 weeks data expected late Q2 2025.

## SEC filing metadata
- accession: 0001437749-24-037053
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924037053/0001437749-24-037053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924037053/crvo20241209_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-037053
- JSON: https://secwatch.observer/filing/0001437749-24-037053.json
- Plain text: https://secwatch.observer/filing/0001437749-24-037053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.